Clinical Trials Directory

Trials / Completed

CompletedNCT01141127

Tranexamic Acid (TXA) in Pediatric Cardiac Surgery

Tranexamic Acid (TXA) During Pediatric Cardiac Surgery: A Prospective Randomised Study Comparing Two Dosing Regimens

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Centre Chirurgical Marie Lannelongue · Academic / Other
Sex
All
Age
12 Months – 12 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine tranexamic acid plasma levels in children undergoing cardiac surgery at risk of bleeding and to compare two dosing regimens.

Detailed description

Tranexamic acid (TXA) is administered intravenously to prevent bleeding associated with cardiac surgery and by pass in adult and children. The pharmacokinetic of this product is unknown in the pediatric population. Only a few studies report a clinical efficacy with different dosages. The purpose of this study is to determine the plasma level of TXA using two different administrations methods: continuous versus intermittent. The second objective is to determine whether fibrinolysis decreased. The population consists in children weighting 10 to 30 Kilos, undergoing cardiac surgery and at high risk of bleeding.

Conditions

Interventions

TypeNameDescription
DRUGTranexamic AcidComparison of two dosage regimen of Tranexamic Acid

Timeline

Start date
2010-06-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2010-06-10
Last updated
2014-07-23

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01141127. Inclusion in this directory is not an endorsement.